ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2015 Financial Results
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 31, 2015, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2015 and its guidance for its 2016 fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-312-0951; the conference ID is 2265897. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through August 14, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche’s Kadcyla® is the first marketed product with ImmunoGen’s ADC technology. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150715005083/en/
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
[email protected]
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hertz Q1 results to be more 'challenging' after CEO change, but there's hope: MS
- Li-Cycle (LICY) Provides Business Update, Following Announcement of $75 Million Investment from Glencore
- Deutsche Bank Downgrades Veradigm Inc (MDRX) to Hold
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!